NeuroEM Therapeutics is developing a self-contained head device to prevent and to treat Alzheimer's Disease (AD) with electromagnetic waves -- a therapy that the principals of the firm have pioneered & used successfully in AD animal studies. There is currently no effective "drug" to prevent or treat AD and pricipals of the firm judge it unlikely that any will be developed in the foreseeable future. Addressing the need of the 10 million Americans who have AD or who are pre-symptomatic for AD, if the NeuroEM Therapeutics is device is clinically successful, it could rovide âin homeâ electromagnetic treatment to the brains of Alzheimerâs patients. Used for 1-2 hours daily, it is suggested that the device will directly attack the Alzheimerâs Disease process would not hinder daily activities and would be employed at the discretion of those medical professional with expertise in diagnosis memory diso
